There is a dramatic increase in the prevalence of nonalcoholic fatty liver disease, which is slowly turning into apandemic as well as a major challenge across the world. Nonalcoholic fatty liver disease is described a...There is a dramatic increase in the prevalence of nonalcoholic fatty liver disease, which is slowly turning into apandemic as well as a major challenge across the world. Nonalcoholic fatty liver disease is described as a range ofliver conditions such as fat accumulation, hepatic steatosis, or end-stage liver disease. Patients with nonalcoholicfatty liver disease are asymptomatic and their mortality is higher than people without nonalcoholic fatty liverdisease. The pathogenesis of nonalcoholic fatty liver disease has not been clearly determined yet. The “two hits”hypothesis is designed to explain the pathogenesis of nonalcoholic fatty liver disease. Dyslipidemia, oxidativestress, insulin resistance, obesity, and chronic inflammation are some of the morbidities involved in the progressionof nonalcoholic fatty liver disease. Chicory (Cichorium intybus L.) is an herbaceous perennial, known as chicory.Chicory contains various compounds, such as vitamins, sonchuside A, caffeic acid derivatives,fructo-oligosaccharides, chlorogenic acid, magnolialide, polysaccharides, coumarins, phenolic acids, terpenoids,flavonoids, polyphenol, cichoriosides, ixerisosides, eudesmanolides, inulin, bitter sesquiterpene lactones, andalkaloids. Current research has revealed that chicory supplementation might be effective in the treatment ofnonalcoholic fatty liver disease. The anti-inflammatory, antihepatotoxic, antihyperlipidemic, antidiabetic,antihyperglycemic, and antioxidant properties of chicory provide plausible mechanisms by which chicory mayaffect the various steps of disease progression and severity. Existing studies have shown that chicorysupplementation has beneficial effects on nonalcoholic fatty liver disease, but the existence of only one humanstudy and possible side effects of chicory necessitate further studies.展开更多
AIM:To investigate the hepatoprotective effect of a Cichorium intybus L.extract(CIE)on CCl4-induced hepatic fibrosis in rats.METHODS:Seventy-two male Wistar albino rats were randomly divided into six groups of twelve ...AIM:To investigate the hepatoprotective effect of a Cichorium intybus L.extract(CIE)on CCl4-induced hepatic fibrosis in rats.METHODS:Seventy-two male Wistar albino rats were randomly divided into six groups of twelve rats each.The normal control group was allowed free access to food and water.Liver injury was performed in the remaining five groups with an i.p.injection of a 1.0mL/kg CCl4 and olive oil(2:3 v/v)mixture,twice weekly for 8 weeks.All rats,with the exception of the injury model group,were intragastrically(i.g.,)administered quantum satis(q.s.)dosages[CIE group:6,18,and 54 mg/kg,respectively;Fu Fang Bie Jia Ruan Gan Pian(FFBJRGP)group:780 mg/kg].The oral administration of different drugs was performed on the day before CCl4 administration and subsequently once per day for8 wk.The serum levels of aspartate aminotransferase(AST),alanine aminotransferase(ALT),hexadecenoic acid(HA),laminin(LN),hydroxyproline(Hyp),and glutathione(GSH),malondialdehyde(MDA)and superoxide dismutase(SOD)in the rat livers were measured.Histopathological changes in the liver were assessed for each group using HE staining and a Masson Trichrome examination.The expression of transforming growth factor-β1(TGF-β1)andα-smooth muscle actin(α-SMA)was examined by immunohistochemical analysis.RESULTS:CIE at oral doses of 6,18,and 54 g/kg per day showed a significant hepatoprotective effect,especially at a dose of 54 g/kg per day.CIE doses reduced the levels of AST(149.04±34.44,P<0.01),ALT(100.72±27.19,P<0.01),HA(548.50±65.09,P<0.01),LN(28.69±3.32,P<0.01)and Hyp(263.33±75.82,P<0.01).With regards to hepatoprotective activity,the CIE dose of 54 g/kg per day produced the largest significant effect by increasing GSH(3.11±0.81),SOD(269.98±33.77,P<0.01)and reducing MDA(2.76±0.51,P<0.01)levels in the liver.The expressions of TGF-β1 andα-SMA were measured by immunohistology and found to be significantly reduced by CIE in a dose-dependent manner.展开更多
The prevalence of nonalcoholic fatty liver disease (NAFLD) as a metabolic disorder affecting the liver function is rapidly increasing and there is a need to develop new and more efficient treatment. This study was des...The prevalence of nonalcoholic fatty liver disease (NAFLD) as a metabolic disorder affecting the liver function is rapidly increasing and there is a need to develop new and more efficient treatment. This study was designed to evaluate the protective effect of Cichorium intybus L. and Cinnamon mixture infusion (2.5 and 0.5 g/100mL and twice/day) on patients with NAFLD. This before-after clinical trial study was performed on 25 patients with NAFLD. They were administered the mixture of extract prepared in special bags twice a day for 30 days. Hepatic and metabolic markers of NAFLD like alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphates (ALP), fasting blood sugar (FBS), cholesterol (chol), triglycerides (TG), high-density lipoprotein (HDL) and low-density lipoprotein (LDL) in plasma and also, fatty liver ultrasonographic grading were determined before and after using the extracts. 30-day treatment with extracts in NAFLD patients resulted in a significant decrease in ALT and AST. FBS, TG and ALP were also decreased after administration of the extracts but not significantly. A significant linear correlation was found between age and ALP, and between gender and liver enzymes. It is concluded that the mixture of Cichorium intybus L. and Cinnamon extracts has some benefits in NAFLD patients making them valuable for future investigations.展开更多
With the rapid social development,people s living habits have undergone great changes.Fast-paced lifestyles have led to an increase in people s unhealthy living habits,especially in diet,such as unreasonable dietary s...With the rapid social development,people s living habits have undergone great changes.Fast-paced lifestyles have led to an increase in people s unhealthy living habits,especially in diet,such as unreasonable dietary structure and irregular diet.In this situation,the number of patients with hyperuricemia has also been increasing,and the hyperuricemia trend is becoming younger.Clinically,western medicines for lowering uric acid are commonly used,which are not safe and have the risk of injuring the liver and kidney functions.Cichorium intybus L.as a medicinal and edible material,plays an important role in treating the hyperuricemia.Recent studies have shown that C.intybus has significant effect of lowering the uric acid.This paper reviewed the experimental studies of C.intybus inhibiting uric acid production and promoting uric acid excretion,discussed its therapeutic effects and action mechanism,to provide a reference for the development of C.intybus drugs for lowering the uric acid.展开更多
文摘There is a dramatic increase in the prevalence of nonalcoholic fatty liver disease, which is slowly turning into apandemic as well as a major challenge across the world. Nonalcoholic fatty liver disease is described as a range ofliver conditions such as fat accumulation, hepatic steatosis, or end-stage liver disease. Patients with nonalcoholicfatty liver disease are asymptomatic and their mortality is higher than people without nonalcoholic fatty liverdisease. The pathogenesis of nonalcoholic fatty liver disease has not been clearly determined yet. The “two hits”hypothesis is designed to explain the pathogenesis of nonalcoholic fatty liver disease. Dyslipidemia, oxidativestress, insulin resistance, obesity, and chronic inflammation are some of the morbidities involved in the progressionof nonalcoholic fatty liver disease. Chicory (Cichorium intybus L.) is an herbaceous perennial, known as chicory.Chicory contains various compounds, such as vitamins, sonchuside A, caffeic acid derivatives,fructo-oligosaccharides, chlorogenic acid, magnolialide, polysaccharides, coumarins, phenolic acids, terpenoids,flavonoids, polyphenol, cichoriosides, ixerisosides, eudesmanolides, inulin, bitter sesquiterpene lactones, andalkaloids. Current research has revealed that chicory supplementation might be effective in the treatment ofnonalcoholic fatty liver disease. The anti-inflammatory, antihepatotoxic, antihyperlipidemic, antidiabetic,antihyperglycemic, and antioxidant properties of chicory provide plausible mechanisms by which chicory mayaffect the various steps of disease progression and severity. Existing studies have shown that chicorysupplementation has beneficial effects on nonalcoholic fatty liver disease, but the existence of only one humanstudy and possible side effects of chicory necessitate further studies.
基金Supported by The Key Projects of the National Science and Technology Pillar Program No.2012BAI30B02
文摘AIM:To investigate the hepatoprotective effect of a Cichorium intybus L.extract(CIE)on CCl4-induced hepatic fibrosis in rats.METHODS:Seventy-two male Wistar albino rats were randomly divided into six groups of twelve rats each.The normal control group was allowed free access to food and water.Liver injury was performed in the remaining five groups with an i.p.injection of a 1.0mL/kg CCl4 and olive oil(2:3 v/v)mixture,twice weekly for 8 weeks.All rats,with the exception of the injury model group,were intragastrically(i.g.,)administered quantum satis(q.s.)dosages[CIE group:6,18,and 54 mg/kg,respectively;Fu Fang Bie Jia Ruan Gan Pian(FFBJRGP)group:780 mg/kg].The oral administration of different drugs was performed on the day before CCl4 administration and subsequently once per day for8 wk.The serum levels of aspartate aminotransferase(AST),alanine aminotransferase(ALT),hexadecenoic acid(HA),laminin(LN),hydroxyproline(Hyp),and glutathione(GSH),malondialdehyde(MDA)and superoxide dismutase(SOD)in the rat livers were measured.Histopathological changes in the liver were assessed for each group using HE staining and a Masson Trichrome examination.The expression of transforming growth factor-β1(TGF-β1)andα-smooth muscle actin(α-SMA)was examined by immunohistochemical analysis.RESULTS:CIE at oral doses of 6,18,and 54 g/kg per day showed a significant hepatoprotective effect,especially at a dose of 54 g/kg per day.CIE doses reduced the levels of AST(149.04±34.44,P<0.01),ALT(100.72±27.19,P<0.01),HA(548.50±65.09,P<0.01),LN(28.69±3.32,P<0.01)and Hyp(263.33±75.82,P<0.01).With regards to hepatoprotective activity,the CIE dose of 54 g/kg per day produced the largest significant effect by increasing GSH(3.11±0.81),SOD(269.98±33.77,P<0.01)and reducing MDA(2.76±0.51,P<0.01)levels in the liver.The expressions of TGF-β1 andα-SMA were measured by immunohistology and found to be significantly reduced by CIE in a dose-dependent manner.
文摘The prevalence of nonalcoholic fatty liver disease (NAFLD) as a metabolic disorder affecting the liver function is rapidly increasing and there is a need to develop new and more efficient treatment. This study was designed to evaluate the protective effect of Cichorium intybus L. and Cinnamon mixture infusion (2.5 and 0.5 g/100mL and twice/day) on patients with NAFLD. This before-after clinical trial study was performed on 25 patients with NAFLD. They were administered the mixture of extract prepared in special bags twice a day for 30 days. Hepatic and metabolic markers of NAFLD like alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphates (ALP), fasting blood sugar (FBS), cholesterol (chol), triglycerides (TG), high-density lipoprotein (HDL) and low-density lipoprotein (LDL) in plasma and also, fatty liver ultrasonographic grading were determined before and after using the extracts. 30-day treatment with extracts in NAFLD patients resulted in a significant decrease in ALT and AST. FBS, TG and ALP were also decreased after administration of the extracts but not significantly. A significant linear correlation was found between age and ALP, and between gender and liver enzymes. It is concluded that the mixture of Cichorium intybus L. and Cinnamon extracts has some benefits in NAFLD patients making them valuable for future investigations.
基金Supported by Project of Special Fund Project for Innovation Driven Development of Guangxi(Gui Ke AA17202046)Project of Guangxi Natural Science Foundation(2020GXNSFAA238026)+8 种基金Project of Guangxi Key Laboratory of Zhuang&Yao Medicine(GXZYZZ2020-05)The First-Class Subject of Traditional Chinese Medicine(Ethnic Pharmacy)in Guangxi(Gui Jiao Ke Yan[2018]12)Collaborative Innovation Center of Zhuang&Yao Medicine(Gui Jiao Ke Yan[2013]20)Guangxi Province Key Laboratory of Zhuang&Yao Medicine(Gui Ke Ji Zi[2014]32)The Eighth Batch of Special Experts Project of Guangxi Zhuang Autonomous Region(Study on quality standard of Zhuang&Yao medicine,Gui Ren Cai Tong Zi[2019]13)Cultivating Highlevel Talent Teams in the Qi Huang Project of Guangxi University of Chinese Medicine(2018002)Program for Innovative Research Team of High Education and Outstanding Scholar in Guang Xi(Gui Jiao Shi Fan[2019]52)Guangxi One Thousand Young and Middle-aged College and University Backbones Teachers Cultivation Program(Gui Jiao Ren[2019]5)Project of Guangxi Science and Technology Base and Talent(Gui Ke AD20238058)。
文摘With the rapid social development,people s living habits have undergone great changes.Fast-paced lifestyles have led to an increase in people s unhealthy living habits,especially in diet,such as unreasonable dietary structure and irregular diet.In this situation,the number of patients with hyperuricemia has also been increasing,and the hyperuricemia trend is becoming younger.Clinically,western medicines for lowering uric acid are commonly used,which are not safe and have the risk of injuring the liver and kidney functions.Cichorium intybus L.as a medicinal and edible material,plays an important role in treating the hyperuricemia.Recent studies have shown that C.intybus has significant effect of lowering the uric acid.This paper reviewed the experimental studies of C.intybus inhibiting uric acid production and promoting uric acid excretion,discussed its therapeutic effects and action mechanism,to provide a reference for the development of C.intybus drugs for lowering the uric acid.
